Post by Gastric Cancer Foundation

The FDA granted orphan drug designation to HanchorBio for its novel SIRPα-Fc pathway inhibitor to treat advanced gastric tumors. The drug is being tested in combination with chemotherapy and Cyramza (ramucirumab) and has demonstrated significant efficacy in early trials. Via @CancerNetwrk